Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Clinical pharmacokinetics of verteporfin.

Houle JM, Strong A.

J Clin Pharmacol. 2002 May;42(5):547-57.

PMID:
12017349
2.

Simple, reliable and fast spectrofluorometric method for determination of plasma Verteporfin (Visudyne) levels during photodynamic therapy for choroidal neovascularization.

Aquaron R, Forzano O, Murati JL, Fayet G, Aquaron C, Ridings B.

Cell Mol Biol (Noisy-le-grand). 2002 Dec;48(8):925-30. Erratum in: Cell Mol Biol (Noisy-le-grand). 2003 Feb;49(1):123.

PMID:
12699252
3.

Spotlight on verteporfin in subfoveal choroidal neovascularisation.

Keam SJ, Scott LJ, Curran MP.

Drugs Aging. 2004;21(3):203-9. Review.

PMID:
14979737
5.
6.

Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation.

Keam SJ, Scott LJ, Curran MP.

Drugs. 2003;63(22):2521-54. Review.

PMID:
14609361
7.

Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.

Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES, Zografos L, Piguet B, Pournaras CJ, Donati G, Lane AM, Birngruber R, van den Berg H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM.

Arch Ophthalmol. 1999 Sep;117(9):1177-87. Erratum in: Arch Ophthalmol 2000 Apr;118(4):488.

PMID:
10496389
9.

[Clinical trial of verteporfin photodynamic therapy in Chinese age-related macular degeneration with subfoveal predominant choroidal neovascularization patients].

Chen YX, Ge J, Yan M, Jin CJ, Zhang MX, Dong FT, Lu F, Zhang CF, Zhao JL.

Zhonghua Yan Ke Za Zhi. 2007 Mar;43(3):198-205. Chinese.

PMID:
17605900
11.

Verteporfin therapy in age-related macular degeneration (VAM): an open-label multicenter photodynamic therapy study of 4,435 patients.

Bessler NM; Vam Study Writing Committee..

Retina. 2004 Aug;24(4):512-20. Erratum in: Retina. 2004 Dec;24(6):990.

PMID:
15300071
12.

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group..

Arch Ophthalmol. 2001 Feb;119(2):198-207.

PMID:
11176980
13.

Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.

Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao Y, Immonen I, Lim JI, Menchini U, Naor J, Potter MJ, Reaves A, Rosenfeld PJ, Slakter JS, Soucek P, Strong HA, Wenkstern A, Su XY, Yang YC; Visudyne in Minimally Classic Choroidal Neovascularization Study Group..

Arch Ophthalmol. 2005 Apr;123(4):448-57.

PMID:
15824216
14.

Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes.

Verteporfin Roundtable 2000 and 2001 Participants.; Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group principal investigators.; Verteporfin in photodynamic therapy (VIP) study group principal investigators..

Retina. 2002 Feb;22(1):6-18. Review.

PMID:
11884872
15.

Verteporfin.

Scott LJ, Goa KL.

Drugs Aging. 2000 Feb;16(2):139-46; discussion 147-8. Review.

PMID:
10755329
16.

A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes.

Sickenberg M, Schmidt-Erfurth U, Miller JW, Pournaras CJ, Zografos L, Piguet B, Donati G, Laqua H, Barbazetto I, Gragoudas ES, Lane AM, Birngruber R, van den Bergh H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM.

Arch Ophthalmol. 2000 Mar;118(3):327-36.

PMID:
10721954
17.

[Preclinical and clinical profile of verteporfin, a potent photodynamic therapy drug for CNV secondary to AMD].

Arita J, Okuyama T.

Nihon Yakurigaku Zasshi. 2004 Dec;124(6):435-44. Review. Japanese.

PMID:
15572848
18.

Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.

Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, Lewis H, Schmidt-Erfurth U, Slakter JS, Bressler SB, Manos K, Hao Y, Hayes L, Koester J, Reaves A, Strong HA; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group..

Arch Ophthalmol. 2002 Nov;120(11):1443-54.

PMID:
12427056
19.

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4.

Azab M, Benchaboune M, Blinder KJ, Bressler NM, Bressler SB, Gragoudas ES, Fish GE, Hao Y, Haynes L, Lim JI, Menchini U, Miller JW, Mones J, Potter MJ, Reaves A, Rosenfeld PJ, Strong A, Su XY, Slakter JS, Schmidt-Erfurth U, Sorenson JA; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.; Verteporfin in Photodynamic Therapy (VIP) Study Group..

Retina. 2004 Feb;24(1):1-12.

PMID:
15076937
20.

Supplemental Content

Support Center